Literature DB >> 24583319

Drug treatment of epilepsy in adults.

Dieter Schmidt1, Steven C Schachter.   

Abstract

Epilepsy is a serious, potentially life shortening brain disorder, the symptoms of which can be successfully treated in most patients with one or more antiepileptic drug. About two in three adults with new onset epilepsy will achieve lasting seizure remission on or off these drugs, although around half will experience mild to moderately severe adverse effects. Patients with epilepsy, especially the 20-30% whose seizures are not fully controlled with available drugs (drug resistant epilepsy), have a significantly increased risk of death, as well as psychiatric and somatic comorbidities, and adverse effects from antiepileptic drugs. Newer drugs have brought more treatment options, and some such as levetiracetam cause fewer drug interactions and less hypersensitivity than older ones. However, they do not reduce the prevalence of drug resistant epilepsy or prevent the development of epilepsy in patients at high risk, such as those with a traumatic brain injury. The development of antiepileptic drugs urgently needs to be revitalized so that we can discover more effective antiseizure drugs for the treatment of drug resistant epilepsy, including catastrophic forms. Antiepileptogenic agents to prevent epilepsy before the first seizure in at risk patients and disease modifying agents to control ongoing severe epilepsy associated with progressive underlying disease are also needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24583319     DOI: 10.1136/bmj.g254

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  62 in total

1.  Epilepsy management: newer agents, unmet needs, and future treatment strategies.

Authors:  C Lee Ventola
Journal:  P T       Date:  2014-11

2.  Semaphorin 4D promotes inhibitory synapse formation and suppresses seizures in vivo.

Authors:  Daniel W M Acker; Irene Wong; Mihwa Kang; Suzanne Paradis
Journal:  Epilepsia       Date:  2018-05-25       Impact factor: 5.864

3.  Triheptanoin alters [U-13C6]-glucose incorporation into glycolytic intermediates and increases TCA cycling by normalizing the activities of pyruvate dehydrogenase and oxoglutarate dehydrogenase in a chronic epilepsy mouse model.

Authors:  Tanya McDonald; Mark P Hodson; Ilya Bederman; Michelle Puchowicz; Karin Borges
Journal:  J Cereb Blood Flow Metab       Date:  2019-03-19       Impact factor: 6.200

Review 4.  The paroxysmal depolarization shift in epilepsy research.

Authors:  Matej Hotka; Helmut Kubista
Journal:  Int J Biochem Cell Biol       Date:  2018-12-14       Impact factor: 5.085

5.  Preparation of Nanocrystals for Insoluble Drugs by Top-Down Nanotechnology with Improved Solubility and Bioavailability.

Authors:  Xun Zhang; Zhiguo Li; Jing Gao; Zengming Wang; Xiang Gao; Nan Liu; Meng Li; Hui Zhang; Aiping Zheng
Journal:  Molecules       Date:  2020-02-28       Impact factor: 4.411

6.  A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.

Authors:  Todd M Conner; Ronald C Reed; Tao Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

Review 7.  The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience.

Authors:  Bernhard J Steinhoff
Journal:  Ther Adv Neurol Disord       Date:  2015-05       Impact factor: 6.570

Review 8.  The pharmacogenomics of valproic acid.

Authors:  Miao-Miao Zhu; Hui-Lan Li; Li-Hong Shi; Xiao-Ping Chen; Jia Luo; Zan-Ling Zhang
Journal:  J Hum Genet       Date:  2017-09-07       Impact factor: 3.172

Review 9.  Treatment of Epilepsy in the Elderly.

Authors:  Paul V Motika; David C Spencer
Journal:  Curr Neurol Neurosci Rep       Date:  2016-11       Impact factor: 5.081

10.  Risk of Seizures Associated with Antidepressant Use in Patients with Depressive Disorder: Follow-up Study with a Nested Case-Control Analysis Using the Clinical Practice Research Datalink.

Authors:  Marlene Bloechliger; Alessandro Ceschi; Stephan Rüegg; Hugo Kupferschmidt; Stephan Kraehenbuehl; Susan S Jick; Christoph R Meier; Michael Bodmer
Journal:  Drug Saf       Date:  2016-04       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.